Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases.

European journal of pharmacology - 5 Oct 2020

Bouscary Alexandra, Quessada Cyril, René Frédérique, Spedding Michael, Henriques Alexandre, Ngo Shyuan, Loeffler Jean-Philippe

Abstract excerpt

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease in adults. While it is primarily characterized by the death of upper and lower motor neurons, there is a significant metabolic component involved in the progression of the disease. Two-thirds of ALS patients have metabolic alterations that are associated with the severity of symptoms. In ALS, as in other neurodegenerative diseases, the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis
Share to beta-Glucosidase

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Repositioning

Share to Glucosylceramidase

Share to Nerve Degeneration

Share to Neuroprotective Agents

Share to Spinal Cord

Share to Superoxide Dismutase-1

Source

Identifiers

PMID: 32739173
DOI: 10.1016/j.ejphar.2020.173446

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Drug repositioning in neurodegeneration: An overview of the use of ambroxol in neurodegenerative diseases.PMID 32739173Read ↗

Glucocerebrosidase mutations and Parkinson disease.Semantic proximity Read ↗

Modest improvement of metabolic and behavioral deficits with long-term ambroxol treatment in a Pink1-/-SNCAA53T double mutant mouse model of Parkinson's disease.Semantic proximity Read ↗

Ambroxol-induced rescue of defective glucocerebrosidase is associated with increased LIMP-2 and saposin C levels in GBA1 mutant Parkinson's disease cells.Semantic proximity Read ↗

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations: A Nonrandomized, Noncontrolled Trial.Semantic proximity Read ↗

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher diseaseSemantic proximity Read ↗

Molecular mechanisms of the ambroxol action in Gaucher disease and GBA1 mutation-associated Parkinson disease.Semantic proximity Read ↗

Cellular and biochemical response to chaperone versus substrate reduction therapies in neuropathic Gaucher disease.Semantic proximity Read ↗

Ambroxol reverses tau and α-synuclein accumulation in a cholinergic N370S GBA1 mutation model.Semantic proximity Read ↗

Inhibition of SOD1 trimerization is a novel drug target for ALS diseaseSemantic proximity Read ↗

Pharmacological chaperone therapy for the treatment of inborn errors of metabolismSemantic proximity Read ↗

Combined beta-glucosylceramide and ambroxol hydrochloride in patients with Gaucher related Parkinson disease: From clinical observations to drug development.Semantic proximity Read ↗

Multi-omic analysis of selectively vulnerable motor neuron subtypes implicates altered lipid metabolism in ALSSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.